The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National and Technology Major Project.
Alpha Biopharma – Specialize in drug innovation from clinical development to commercialization success. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha Biopharma establishes strategic partnership with leading international pharmaceutical company/R&D institute.
- +86 21 63862192
- Shanghai：Unit 05-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai
- Beijing：Room 2512, The Place Tower, No. 9 Guanghua Road, Chaoyang District, Beijing